Literature DB >> 7743470

Prognostic value of erb-B2 and myc amplification in breast cancer imprints.

U Lönn1, S Lönn, B Nilsson, B Stenkvist.   

Abstract

BACKGROUND: Amplification of erb-B2 and myc shows prognostic value in patients with operable breast cancer. Amplification is usually detected in tumor samples remaining after pathologic work-up, preventing the examination of small tumors.
METHODS: Tumor imprints that contained low numbers of contaminating normal cells were obtained from small tumors. The prognostic value of erb-B2 and myc amplification in imprint breast preparations was examined, using the polymerase chain reaction (PCR) to determine gene copy number. Tumor material was obtained from 162 patients with breast cancer operated 1975-1976.
RESULTS: Amplification of erb-B2 existed in 21% and myc in 16% of the patients. Both erb-B2 and myc amplification showed prognostic significance in univariate analysis for survival and relapse free survival. In multivariate analysis, erb-B2 was a significant factor. In small tumors less than 13 mm in greatest dimension, erb-B2 showed prognostic significance for survival but not for relapse free survival.
CONCLUSIONS: The use of imprints/PCR allows the detection of gene amplification in breast cancer. The procedure is suitable for the analysis of small tumors and can be used to examine very small tumors, such as those detected mammographically.

Entities:  

Mesh:

Year:  1995        PMID: 7743470     DOI: 10.1002/1097-0142(19950601)75:11<2681::aid-cncr2820751107>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Development and characterization of new immortalized human breast cell lines

Authors: 
Journal:  Cytotechnology       Date:  1998       Impact factor: 2.058

Review 3.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

4.  Human papillomavirus DNA and oncogene alterations in colorectal tumors.

Authors:  Luis Orlando Pérez; Gisela Barbisan; Anabel Ottino; Horacio Pianzola; Carlos Daniel Golijow
Journal:  Pathol Oncol Res       Date:  2010-03-17       Impact factor: 3.201

5.  A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer.

Authors:  B A Jennings; J E Hadfield; S D Worsley; A Girling; G Willis
Journal:  Mol Pathol       Date:  1997-10

6.  Identification of high-risk breast cancer patients from genetic changes of their tumors.

Authors:  M Watatani; H Inui; K Nagayama; Y Imanishi; K Nishimura; Y Hashimoto; E Yamauchi; T Hojo; Y Kotsuma; M Yamato; N Matsunami; M Yasutomi
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

Review 7.  Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis.

Authors:  József Tímár; Orsolya Csuka; Zsolt Orosz; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

Review 8.  Tumor microenvironment: becoming sick of Myc.

Authors:  Jonathan R Whitfield; Laura Soucek
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

9.  MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.

Authors:  Aatur D Singhi; Ashley Cimino-Mathews; Robert B Jenkins; Fusheng Lan; Stephanie R Fink; Hind Nassar; Russell Vang; John H Fetting; Jessica Hicks; Saraswati Sukumar; Angelo M De Marzo; Pedram Argani
Journal:  Mod Pathol       Date:  2011-11-04       Impact factor: 7.842

10.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.

Authors:  S L Deming; S J Nass; R B Dickson; B J Trock
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.